Fresenius Medical Care, North AmericaAugust 13, 2020

FDA 483 - Fresenius Medical Care, North America - August 13, 2020

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fresenius Medical Care, North America

Record Details

Fresenius Medical Care, North America in Ogden, UT, a sterile drug manufacturer, was cited for two observations during an FDA inspection. The firm failed to thoroughly investigate unexplained discrepancies related to rejected batches and lacked adequate written procedures for production and process controls. These deficiencies included issues with retaining critical alarm logs and controlling certificates of analysis.

Company: Fresenius Medical Care, North America
Inspection Date: August 13, 2020
Product Type: Drugs
Office: Denver District Office
Person: Nayan J. Patel (Senior Lead Reviewer and Intercenter Consult Team Leader)

Open in Dashboard

ID · f722a98a-9b92-40b1-8c0a-5c07ebf6c6a6